IL295265A - מערכות ריפוי גנטי ושיטות קשורות לטיפול באיבוד שמיעה - Google Patents

מערכות ריפוי גנטי ושיטות קשורות לטיפול באיבוד שמיעה

Info

Publication number
IL295265A
IL295265A IL295265A IL29526522A IL295265A IL 295265 A IL295265 A IL 295265A IL 295265 A IL295265 A IL 295265A IL 29526522 A IL29526522 A IL 29526522A IL 295265 A IL295265 A IL 295265A
Authority
IL
Israel
Prior art keywords
promoters
vector
tmprss3
hearing loss
adeno
Prior art date
Application number
IL295265A
Other languages
English (en)
Original Assignee
Rescue Hearing Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/783,148 external-priority patent/US12391936B2/en
Application filed by Rescue Hearing Inc filed Critical Rescue Hearing Inc
Publication of IL295265A publication Critical patent/IL295265A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36036—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of the outer, middle or inner ear
    • A61N1/36038—Cochlear stimulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0526—Head electrodes
    • A61N1/0541—Cochlear electrodes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
IL295265A 2020-02-05 2021-02-04 מערכות ריפוי גנטי ושיטות קשורות לטיפול באיבוד שמיעה IL295265A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/783,148 US12391936B2 (en) 2017-03-17 2020-02-05 Gene therapy systems and related methods for treatment of hearing loss
PCT/US2021/016653 WO2021158814A1 (en) 2020-02-05 2021-02-04 Gene therapy systems and related methods for treatment of hearing loss

Publications (1)

Publication Number Publication Date
IL295265A true IL295265A (he) 2022-10-01

Family

ID=77200377

Family Applications (1)

Application Number Title Priority Date Filing Date
IL295265A IL295265A (he) 2020-02-05 2021-02-04 מערכות ריפוי גנטי ושיטות קשורות לטיפול באיבוד שמיעה

Country Status (9)

Country Link
EP (1) EP4081232A4 (he)
JP (1) JP2023513116A (he)
KR (1) KR20220137652A (he)
CN (1) CN116096391A (he)
AU (1) AU2021216405A1 (he)
BR (1) BR112022015345A2 (he)
CA (1) CA3166104A1 (he)
IL (1) IL295265A (he)
WO (1) WO2021158814A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260026049A (ko) * 2023-06-15 2026-02-25 리제너론 파아마슈티컬스, 인크. 청력 장애에 대한 유전자 치료

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US9265933B2 (en) * 2005-09-08 2016-02-23 Massachusetts Eye And Ear Infirmary Cochlear implants containing biological cells and uses thereof
KR100977525B1 (ko) * 2008-04-11 2010-08-23 주식회사 뉴로바이오시스 적외선 통신 방식의 귓속형 인공 와우 장치
JP2020509786A (ja) * 2017-03-17 2020-04-02 レスキュー ヒヤリング インコーポレイテッド 聴覚損失の治療のための遺伝子治療構成物および方法
EP3762040A4 (en) * 2018-03-05 2022-01-05 Children's Medical Center Corporation COMPOSITIONS AND METHODS OF ADMINISTRATION OF NUCLEIC ACIDS TO COCHLEAR AND VESTIBULAR CELLS

Also Published As

Publication number Publication date
WO2021158814A1 (en) 2021-08-12
EP4081232A4 (en) 2024-02-28
BR112022015345A2 (pt) 2022-12-06
EP4081232A1 (en) 2022-11-02
CA3166104A1 (en) 2021-08-12
AU2021216405A1 (en) 2022-09-15
CN116096391A (zh) 2023-05-09
JP2023513116A (ja) 2023-03-30
KR20220137652A (ko) 2022-10-12
WO2021158814A9 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
Kleinlogel et al. Emerging approaches for restoration of hearing and vision
Al‐Moyed et al. A dual‐AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock‐out mice
CN112423791B (zh) 将核酸递送至耳蜗和前庭细胞的组合物和方法
EP3595634B1 (en) Gene therapy constructs and methods for treatment of hearing loss
US20210023242A1 (en) Treatment of deafness by gene therapy
Lu et al. Gene therapy with a synthetic adeno-associated viral vector improves audiovestibular phenotypes in Pjvk-mutant mice
Du et al. Rescue of auditory function by a single administration of AAV-TMPRSS3 gene therapy in aged mice of human recessive deafness DFNB8
US20240252681A1 (en) Gene therapy constructs and methods for treatment of hearing loss
Gadenstaetter et al. Inner Ear Gene Therapy: An Overview from Bench to Bedside: AJ Gadenstaetter et al.
Lahlou et al. Extended time frame for restoring inner ear function through gene therapy in Usher1G preclinical model
Isgrig et al. Combined AAV-mediated gene replacement therapy improves auditory function in a mouse model of human DFNB42 deafness
IL295265A (he) מערכות ריפוי גנטי ושיטות קשורות לטיפול באיבוד שמיעה
Thirumalai et al. Improved optogenetic modification of spiral ganglion neurons for future optical cochlear implants
US12391936B2 (en) Gene therapy systems and related methods for treatment of hearing loss
US12491223B2 (en) Method for treating an auditory neuropathy spectrum disorder
Iranfar AAV-mediated gene therapy restores hearing and central auditory processing in a mouse model of human DFNB16 Deafness
Jin et al. Genetic deafness and gene therapy approaches for treatment
Dell'Aquila Gene therapy for gyrate atrophy of choroid and retina and for USH1B retinitis pigmentosa
Cao Application of Gene Editing to Promote Axon Regeneration in Retinal Ganglion Cells after Optic Nerve Injury